221 Views | 162 Downloads
Betsy Sleath, Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, CB# 7573, Chapel Hill, NC 27599-7573, USA. Email: betsy_sleath@unc.edu.
Betsy Sleath, Robyn Sayner, and Delesha Carpenter contributed to drafting the article.
Kelly Muir, Susan Blalock, and Alan Robin revised it critically for important intellectual content.
Betsy Sleath, Kelly Muir, Annette Giangiacomo, Mary Elizabeth Hartnett, and Alan Robin contributed to conception and design of study.
Kelly Muir, Annette Giangiacomo, Mary Elizabeth Hartnett, and Alan Robin contributed to acquisition of data.
Betsy Sleath, Susan Blalock, Michelle Vitko, and Robyn Sayner contributed to analysis and interpretation of data.
All authors gave final approval of the submitted version of the article.
National Institutes of Health had no role in the design or conduct of this research.
Drs. Sleath, Blalock, Carpenter, Muir, and Sayner indicate no conflict of interest.
Dr. Robin has been a consultant for Biolight, Lupin Pharmaceuticals, and Sucampo and he does paid lectures for Merck and Allergan.
He has been a consultant and has stock options in Glaucos. Dr. Robin is on the board of Aerie Pharmaceuticals.
Dr. Hartnett is a consultant for Axikin Pharmaceuticals.
Dr. Muir receives salary support from a Veterans Affairs Health Services Research & Development Career Development Award.
This project was supported by grant EY018400 from the National Eye Institute and by grant 1UL1TR001111 from the National Center of Research Resources, National Institutes of Health.
Dr. Hartnett was also supported by National Institutes of Health grants EY015130 and EY017011.
© 2016 Elsevier Ireland Ltd